Home World News Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with... World News Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 526 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Zanubrutinib October 26, 2022 Merging the Histologic and Molecular Data Into an Integrated Score Significantly... October 11, 2021 Scientists Find Genetic Changes Linked to Cancer in Children March 4, 2025 FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... July 31, 2024 Load more HOT NEWS FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο Prostate cancer: Lessons Learned from My Breast Cancer
